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Conclusion: The immediate and long-term outcome after TAVI did not differ between
patients with an impaired and preserved LVEF. LVEF ≤35% did not predict adverse
immediate and long-term outcome. These findings indicate that TAVI should not be
withheld in patients with impaired LV function.
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Background: Identifying the optimal fluoroscopic valve projection is important for
successful transcatheter aortic valve replacement (TAVR). We compared angle
predictions from 3-dimensional angiographic reconstructions (3DA) of the aortic root
to those from multidetector computed tomography (MDCT).
Methods: Patients undergoing transfemoral TAVR underwent pre-implant 3DA and
baseline MDCT. Two separate independent operators predicted perpendicular valve
projections for each method prospectively. The angles generated from 3DA and MDCT
as well as the final implant angle were compared to the post deployment perpendicular
valve projection. 3DA reconstructions were generated from a 220 degree rotational
aortic root angiogram during breath hold and rapid ventricular pacing. The shortest
distance from the post deployment perpendicular valve projection to the regression
line of predicted perpendicular valve views were calculated for every patient and
method.
Results: 39 out of 40 patients had adequate image quality for reproducible angle
predictions. There was a significant correlation between 3DA and MDCT for
predictions of perpendicular valve projections (r = 0.682, p<0.001, figure 1). Deviation
from the regression line of predicted angles to the post deployment valve view were
5.1±4.6° for 3DA and 7.9±4.9° for MDCT (p = 0.016). The mean deviation from the
implant angle to the post deployment perpendicular valve view was 1.9±4.6°
RAO/LAO and 5.1±7.2° cranial/caudal.
Conclusion: Both 3DA and MDCT are accurate and safe imaging modalities for
identifying the optimal valve deployment projection in TAVR.
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Background: Patients with severe aortic stenosis (AS) and a history of previous
cardiac surgery who require valvular intervention have an increased peri-operative risk.
Transcatheter aortic valve implantation (TAVI) is increasingly popular in such high-
risk patients. If peripheral vascular disease precludes transfemoral implantation
(TF-TAVI), the transapical approach (TA-TAVI) is used. However this is associated
with pleural disruption and compromise of the left ventricular (LV) continuity. We
sought to evaluate the feasibility of the retrograde, transaortic technique (TAo-TAVI)
using the Edwards SAPIEN valve as an alternative approach avoiding these problems.
Methods: 196 patients with severe aortic stenosis underwent TAVI at St Thomas’
Hospital, London, between January 2008 and March 2011. 59 patients had previously
undergone cardiac surgery and of these 7 patients underwent TAo-TAVI after
considerations of anatomy, risk, LV function and significant respiratory disease. 6 had
previous coronary artery bypass grafting (85.7%) and 1 patient (14.3%) had 2 previous
cardiac operations for resection of subaortic membrane and ventricular septal defect
closure. All patients with CABG had patent grafts including LIMA to LAD and
saphenous vein grafts to native coronaries.
Results: In the TAo-TAVI group the age (mean±SD) was 71.5±13.5 years. 71.4% were
male. Mean logistic EuroScore was 30.4±20.1. Pre-TAVI peak transaortic gradient was
84.6±36.4mmHg and fell to to 13.6±5.7mmHg immediately post-procedure (p=0.002).
All patients underwent successful TAo-TAVI with 23mm (2/6) and 26mm (4/6)
bioprostheses. There were no device related peri-procedural complications. 30-day
mortality was 14.3% (1/7) for TAo-TAVI, 10.0% (3/30)for TA-TAVI and 18.2% (4/22)
for TF-TAVI (p=0.695).
Conclusion: TAo-TAVI is a feasible option in high-risk redo patients with patent
coronary grafts and may provide a preferable access route in these high-risk patients
when TF-TAVI is not possible, avoiding the LV and respiratory complications of TA-
TAVI.
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Background: Transcatheter aortic valve implantation (TAVI) has become an
established treatment for severe aortic stenosis in patients with unacceptable high
surgical risk. Recently, the new AccuTrak delivery system for improved deliverability
of the CoreValve aortic bioprosthesis was launched. It has not been shown yet, if the
new delivery catheter leads to optimized positioning and improved procedural
outcomes.
Methods: We therefore conducted a retrospective single-center analysis comparing
the procedural results after transfemoral CoreValve implantation with or without the
new AccuTrak delivery system.
Results: We evaluated 70 consecutive patients (35 with the original delivery catheter
and 35 with the new AccuTrak catheter) for procedural results after CoreValve
implantation. The use of the AccuTrak delivery catheter resulted in significantly higher
positioning of the CoreValve prosthesis (8.8 mm [7.1 to 11.2 mm] vs. 7.0 mm [5.5 to
9.4 mm]; P= 0.0068) below the annulus (median [interquartile range]). Moreover, the
optimized positioning resulted in reduced rates of significant (≥ grade 2) aortic
regurgitation assessed by postinterventional aortography and echocardiography (P=
0.044 and P=0.0275 respectively). Despite improved positioning, no differences in the
need for permanent pacemaker implantation were observed.
Conclusion: Our retrospective analysis demonstrates improved positioning and
reduced postinterventional aortic regurgitation with the new CoreValve AccuTrak
delivery system. Whether this may also affect the need for permanent pacemaker
insertion or longterm outcome after TAVI needs to be evaluated in larger studies.
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Background: Residual PAR after TAVI is common. However, systematic data on its
severity and its clinical impact are sparse. We, therefore, thought to evaluate incidence,
severity and outcome of residual PAR after TAVI.
Methods: We analyzed data from 167 consecutive TAVI patients treated with either
the Medtronic-CoreValve (n=88) or the Edwards Sapien (n=79) bioprosthesis. PAR
was graded angiographically according to the Sellers criteria at the end of the
procedure.In addition,invasive hemodynamics post implantation(pressure difference:
diastolic aortic pressure – LVEDP (PD DAP–LVEDP)) were analyzed.
Results: TAVI was technically successful in all patients with overall mortality rates of
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9%, 13 % and 20% at 30 days, 6 months and 1 year, respectively. PAR was observed
in 113 patients (67%), 89 (78,8%) showing mild, 21 (18.6%) moderate and 3 (2.7%)
severe PAR. Cardiovascular mortality at 30 days, 6 months and 1-year was significantly
increased in patients with moderate/severe PAR compared to those with no/mild PAR
(4.5 vs. 50.0%, 5.1 vs. 61 % and 6.9 vs. 71 %, respectively, p<0.05) (figure 2). Further
analysis of intraprocedural invasive hemodynamics using the the receiver-operating
characteristic curves suggested PD DAP–LVEDP as a predictor of early and late
mortality with an overall area under the curve of 0.978 (figure 1). The graph indicates
a PD DAP–LVEDP of 18 mmHg as a good predictor of mortality.
Figure 1:The receiver-operating characteristic curves suggested PD DAP–LVEDP as
a predictor of early and late mortality with an overall area under the curve of 0.978
Figure 2: Cardiovascular mortality was significantly increased in patients with
moderate/severe PAR compared to those with no/mild PAR p<0.05) .
Conclusion: Moderate to severe PAR after TAVI was observed in 21% of patients and
associated with an increased cardiovascular mortality. Therefore relevant PAR after
TAVI should not be tolerated and countermeasure (postdilatation, valve in valve
implantation) should be considered, especially with a PD DAP–LVEDP < 18 mm Hg.
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Background: Since the first transcatheter aortic valve implantation (TAVI) in 2002,
there has been a rapid growth in the use of this technique throughout the world.
Identification of pre-procedural predictors of the short and mid-term mortality may
influence patient selection for TAVI. Therefore our purpose was to investigate the
independent predictors for early and mid-term mortality following TAVI.
Methods: In a single center prospective observational study, we included 164
consecutive patients (age 80±8 years, 69 male) with severe symptomatic aortic valve
stenosis who underwent transfemoral TAVI with the Medtronic-CoreValve device
(n=119 patients) or transapical TAVI with the Edwards-SAPIEN device (n=45 patients).
Clinical parameters were obtained from the medical history, electrocardiograms,
angiography, laboratory measurements and transthoracic echocardiography pre- and
post procedurally and at follow up.
Results: Following TAVI 21 patients died within 30 days (12.8%). Independent
predictors for 30-day all cause mortality were a higher left ventricular mass index
(LVMI) (OR:1.01, 95%CI:1.00-1.03, p=0.045 ) and hospitalization more than one week
because of serious symptomatic disease prior to TAVI procedure (OR:4.34, 95%CI:1,4-
13.8, p=0.013). The only independent predictor for one year mortality was a higher
LVMI (HR: 1.01, 95%CI:1.003-1.022, p=0.012).
LVMI predictor for mortality following TAVI
Conclusion: In patients with severe symptomatic aortic valve stenosis treated by TAVI
by transfemoral route or transapical route the 30 day all-cause mortality is predicted
by pre-procedural hospitalization and a higher left ventricular mass index. Left
ventricular mass index is the only independent predictor for one year mortality
following TAVI.
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Myocardial Injury and Electrocardiographic Changes Following Transcatheter
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Background: Uncomplicated transcatheter aortic valve implantation (TAVI)
procedures could be associated with a rise in cardiac markers of myocardial injury.
The reason for that is multifactorial. It has not been evaluated whether this elevation
is associated with new electrocardiographic (ECG) findings after TAVI. We determined
the incidence and the characteristics of ECG changes in patients with troponin elevation
after TAVI.
Methods: Patients with symptomatic severe aortic valve stenosis who underwent
uncomplicated transcatheter aortic valve implantation (TAVI) were evaluated. Troponin
I levels and electrocardiograms were recorded daily, before and for 5 days after the
procedure. In patients with elevated troponin levels, baseline and post-procedural ECG
recordings were compared. The agreement in each ECG finding between the two
recordings was assessed with kappa statistic (the hypothesis that each subject retains
his/her characteristics after TAVI was tested). Overall prevalence of each ECG finding
was compared before vs after TAVI by McNemar test (one sample comparisons of
repeated binary data).
Results: A total of 96 patients were treated with TAVI and 33 patients (17 males, 16
females, mean age 8.5±6.5 yrs)manifested elevated troponin I levels (mean troponin I
= 0.95±1.61). The ECG findings before TAVI showed a significant agreement with the
respective findings after TAVI for every ECG feature except for QTc prolongation
(kappa=0.198, p=0.0191). Abnormal mean QTc (475.9±11.2) was detected before TAVI
in 29.2% of the pts, while normal mean QTc was present in 70.8 % (426.1±14). After
the intervention an abnormal mean QTc (481.8±20.2) was observed in 73.3%
(p<0.001), while a normal mean QTc in 26.7 % (427.9±12.9). In patients who
developed prolongation of QTc (57%), new LBBB was observed in 47% of them.
Conclusion: In patients with Troponin I elevation after TAVI the incidence of
prolonged QTc is increased. This may reflect ischemia as a result of microembolization
or the mechanical effect of the prosthesis itself on the conduction system.
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Predictive factors of major VARC vascular complications following trans-
femoral transcatheter aortic valve implantation
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Background: Management of vascular access complications is a major challenge in
trans-femoral (TF) transcatheter aortic valve implantation (TAVI). Predictive factors
of vascular complications (VC) were not well established in the literature. We sought
to analyze incidence, characteristics and potential predictive factors of VC.
Methods: Single center analysis of an unselected population of patients who underwent
TAVI with the Edwards SAPIEN (ES) and Medtronic CoreValve (MCV) devices via
the TF approach. VC were analyzed and classified according to Valve Academic
Research Consortium (VARC) definition. Baseline clinical and biological
characteristics, as well as ilio-femoral arteries anatomy and diameters were assessed
before valve implantation.
Results: Eighty-five patients (64,7% female; Mean age=83,7±5,9 years; Mean
Euroscore = 20,6±10,8) were included between December 2009 and Mars 2010, using
ES in 87 % and MCV in 13% of cases. VC have occurred in 24.7% of patients (n=13
major and n=8 minor). The 30-day mortality was 19% in patients with major VC
compared to 5.4% in patients without. Female gender, individual height and body
surface, creatinine clearance, mean common femoral artery (CFA) diameter, as well
as the ratio (CFA diameter/sheath diameter)<1 were associated with major VC in
univariate analysis. No procedural factor (valve device, anticoagulation regimen,
arteriotomy technique, operators’ experience) was predictive of complications. In
multivariate analysis, creatinine clearance (HR=0.96 per ml/m2/min 95%CI [0.90-1.0])
and the mean CFA artery diameter (HR=0.42 95% CI [0.2-0.9]) were the only
independent predictors statistically significant with major VC.
Conclusion: The incidence of VARC vascular complication is moderated following
TF TAVI procedures. The mean diameter of the CFA is the best predictive factor of
major VARC vascular complications following TF TAVI procedure. A best pre-
procedural evaluation of ilio-femoral anatomy by CT scan and reduction of sheath
diameter may help to prevent these complications in the future.
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